surpass 3 tirzepatide outcompetes long-acting insulin in managing type 2 diabetes: a meta-analysis of three phase randomized controlled trials Read now: The SURPASS-EARLY trial

With a combo GIP/GLP-1 receptor agonist like Mounjaro and Zepbound, people can lose 20% or more of their weight

According to the University of Rochester Medical Center, a hangover IV drip may be considered if a patient cannot keep anything down, especially water (URMC Health Matters, 2024)

JACC Heart Fail 4:559566 Savarese G, Schrage B, Cosentino F, Lund LH, Rosano GMC, Seferovic P, Butler J (2020) Non-insulin antihyperglycaemic drugs and heart failure: an overview of current evidence from randomized controlled trials

The most common adverse events were gastrointestinal in both the semaglutide (52.8%) and placebo (25%) arms

It's true that one medication has consistently shown better weight loss results in studies (more on that in a sec), but doctors stress that doesnt mean its the bestor most feasiblesolution for everyone